---
title: "GINKGO BIOWORKS HOLDINGS INC C/WTS 16/09/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 19.47 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285611238.md"
datetime: "2026-05-07T20:22:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285611238.md)
  - [en](https://longbridge.com/en/news/285611238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285611238.md)
---

# GINKGO BIOWORKS HOLDINGS INC C/WTS 16/09/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 19.47 M

Revenue: As of FY2026 Q1, the actual value is USD 19.47 M.

EPS: As of FY2026 Q1, the actual value is USD -1.39.

EBIT: As of FY2026 Q1, the actual value is USD -79.74 M.

#### Revenue

GINKGO BIOWORKS HOLDINGS, INC. reported first quarter 2026 revenue of $19 million, a 49% decrease from $38 million in the comparable prior year period . Excluding $7 million of non-cash revenue from a deferred revenue release in Q1 2025, revenue decreased by 37% from $31 million in the comparable prior year period to $19 million in Q1 2026, primarily due to ongoing program rationalization as part of restructuring activities .

#### GAAP Net Loss from Continuing Operations

The GAAP net loss from continuing operations for the first quarter of 2026 was -$76 million, an improvement from -$83 million in the comparable prior year period .

#### Adjusted EBITDA

Adjusted EBITDA for the first quarter of 2026 was -$42 million, compared to -$44 million in the comparable prior year period .

#### Operational Expenses (Continuing Operations)

-   **Cost of other revenue**: $3,098 thousand in Q1 2026, down from $4,090 thousand in Q1 2025 .
-   **Research and development**: $49,920 thousand in Q1 2026, down from $70,923 thousand in Q1 2025 .
-   **General and administrative**: $37,830 thousand in Q1 2026, down from $39,723 thousand in Q1 2025 .
-   **Restructuring charges**: $0 thousand in Q1 2026, down from $4,466 thousand in Q1 2025 .
-   **Total operating expenses**: $90,848 thousand in Q1 2026, down from $119,202 thousand in Q1 2025 .

#### Loss from Operations (Continuing Operations)

Loss from operations was -$71,374 thousand in Q1 2026, improving from -$80,972 thousand in Q1 2025 .

#### Cash Flow and Balances

-   **Cash, Cash Equivalents and Marketable Securities**: The balance as of March 31, 2026, was $373 million .
-   **Net Cash Used in Operating Activities**: Total net cash used in operating activities was -$46,686 thousand in Q1 2026, an improvement from -$51,521 thousand in Q1 2025 .
    -   Net cash used in operating activities from continuing operations: -$46,433 thousand in Q1 2026, compared to -$42,749 thousand in Q1 2025 .
    -   Net cash used in operating activities from discontinued operations: -$253 thousand in Q1 2026, compared to -$8,772 thousand in Q1 2025 .

#### Unique Operational Metrics

GINKGO BIOWORKS HOLDINGS, INC. is targeting to double the size of its Nebula autonomous lab in 2026 . The Cloud Lab, Datapoints, and Solutions offerings are generating revenue and accelerating the development of the autonomous lab .

#### Full Year 2026 Outlook

GINKGO BIOWORKS HOLDINGS, INC. reaffirms its expected total cash burn for the full year 2026 to be between -$150 million and -$125 million .

### Related Stocks

- [DNABW.US](https://longbridge.com/en/quote/DNABW.US.md)

## Related News & Research

- [DNA: Q2 2026 revenue dropped 48% year-over-year, with major autonomous lab contracts secured](https://longbridge.com/en/news/295007946.md)
- [Kemper declares R$ 0.55 per share dividend for Q3 2026](https://longbridge.com/en/news/295131613.md)
- [Apple declares Q3 2026 distribution of R$ 0.05 per unit, payable Aug. 19](https://longbridge.com/en/news/294819600.md)
- [VGP to host webcast on H1 2026 results](https://longbridge.com/en/news/295056101.md)
- [Mobilezone schedules investor video conference on H1 2026 results](https://longbridge.com/en/news/294935560.md)